Introduction {#s1}
============

According to epidemiology, skin cancer including melanoma and non-melanoma is the most common type of cancer in white populations \[[@B1]\]. Statistics show that the incidence of skin cancer has been increasing in Europe and the USA, especially melanoma, in the past two decades \[[@B2],[@B3]\]. Skin cancer has several histological subtypes, including melanoma, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) \[[@B4]\]. Many studies indicate that ultraviolet (UV) exposure is a major risk factor of skin cancer development \[[@B5]-[@B7]\]. However, on the molecular level, the carcinogenic mechanism of UV has not been expounded yet.

*TP53* gene is a tumor suppressor gene which can regulate cell cycle arrest, cell apoptosis and DNA repair \[[@B8]\]. Hence, it is called guardian of genome. Mutations of *TP53* gene are the most common genetic abnormality found in many kinds of human cancers, such as lung cancer, colon cancer, gastric cancer, skin cancer, et al \[[@B9]\]. Arg72Pro polymorphism of *TP53* gene is a G-C transversion at codon 72, resulting in an amino acid change from arginine (Arg) to proline (Pro) \[[@B10]\]. Studies have shown that *TP53* gene plays an important role in the cellular genome protection from UV exposure \[[@B11],[@B12]\]. But the detailed molecular mechanism is unclear.

Many studies in recent years have investigated the association between *TP53* Arg72Pro polymorphism and the risk of skin cancer, but their results remain inconclusive. Thus, we performed this meta-analysis of all eligible case--control studies that have been published to help us for a better understanding of the influence of *TP53* Arg72Pro polymorphism.

Methods {#s2}
=======

Publication Search {#s2.1}
------------------

We searched PubMed for publications up to March 2013, using the terms "TP53," "polymorphism," and "skin cancer." The search was performed without any restrictions on language. Besides, we searched the reference lists of reviews and retrieved articles manually. When the same patient population appeared in several articles, we chose the largest sample size or the most recent one.

Inclusion Criteria {#s2.2}
------------------

The selected studies must have met the following major criteria: (1) well-designed case-control studies to evaluate *TP53* Arg72Pro polymorphism and the risk of skin cancer; (2) skin cancer was diagnosed by pathology; (3) containing useful genotype frequencies; and (4) the distribution of genotypes among controls were in Hardy-Weinberg equilibrium.

Exclusion Criteria {#s2.3}
------------------

The exclusion criteria included: (1) the genotype frequencies or number not presented; (2) animal studies, reviews, case reports, abstracts and family-based studies; (3) duplication of a previous publication.

Data Extraction {#s2.4}
---------------

Two investigators extracted information from eligible studies independently, according to the inclusion and exclusion criteria above. Disagreements were resolved by discussion or a third investigator. The following information was collected: first authors, publication year, ethnicity, characteristics of cases and controls (mean age, distribution of gender), histological type of cases, genotyping method, number of genotypes and total number of cases and controls.

In the paper of Rizzato et al the non coding strand has been genotyped, so we inverted the genotypes in his paper.

Statistical Analysis {#s2.5}
--------------------

The strength of the association between *TP53* Arg72Pro polymorphism and the risk of skin cancer was evaluated by pooled odds ratios (ORs) with 95% confidence intervals (CIs). The pooled ORs for dominant model (Arg/Arg + Pro/Arg versus Pro/Pro), recessive model (Arg/Arg versus Arg/Pro + Pro/Pro), codominant model (Arg/Arg versus Pro/Pro and Arg/Pro versus Pro/Pro) and the allele contrast (Pro allele versus Arg allele) were calculated, respectively. Stratified analyses were performed by ethnicity and histological type of skin cancer. The heterogeneity assumption was assessed by the Chi-square-based Q-test. If P\<0.05 of the Q-test which indicated heterogeneity, the random-effects model was used to calculate the pooled ORs. Otherwise, the fixed-effects model was adopted. The Z test was applied to determine the pooled OR with the significance set at P\<0.05. Potential publication bias was estimated by Begg's funnel plot \[[@B13]\] and Egger's test \[[@B14]\]. P\>0.05 meant no significant publication bias. All above statistical analyses were performed with the STATA software, version 12.0 (StataCorp, College Station, TX, USA). Power analysis was performed using the Power and Sample Size Calculation (PS) program ([[http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize]{.ul}](http://biostat.mc.vanderbilt.edu/wiki/main/powersamplesize)) \[[@B15]\].

Results {#s3}
=======

Study Characteristics {#s3.1}
---------------------

A total of 165 papers were obtained by the publication search published until March 2013, among which twenty met the inclusion criteria \[[@B16]-[@B35]\] ([Figure S1](#pone.0079983.s001){ref-type="supplementary-material"}). The ultimate twenty studies were all in English, involving 5276 skin cancer cases and 5315 controls. The main characteristics were summarized in [Table 1](#pone-0079983-t001){ref-type="table"}.

10.1371/journal.pone.0079983.t001

###### Characteristics of studies included in the meta-analysis.

  First author      Year   Ethnicity   Country                      Cases   Controls                     
  ----------------- ------ ----------- ---------------------------- ------- ---------- ----- ----- ----- -----
  Dokianakis        2000   Caucasian   Greece                       3       5          19    6     41    12
  Marshall          2000   Caucasian   England                      3       18         34    6     39    39
  Bastiaens         2001   Caucasian   The Netherlands              21      131        169   10    72    75
  O\'Connor         2001   Caucasian   Ireland                      1       11         43    4     20    91
  Cairey-Remonnay   2002   Caucasian   France                       4       16         50    5     66    85
  McGregor          2002   Caucasian   England                      0       58         124   5     7     17
  Gustafsson        2004   Caucasian   Sweden                       5       19         30    3     31    62
  de Oliveira       2004   Other       Brazil                       0       0          16    2     9     16
  Gwosdz            2006   Caucasian   Germany                      7       24         18    13    66    114
  Han               2006   Caucasian   USA                          55      294        409   45    297   474
  Pezeshki          2006   Asian       Iran                         10      47         34    86    217   162
  Stefanaki         2007   Caucasian   Greece                       11      44         52    6     66    73
  Bendesky          2007   Other       Mexico                       25      94         122   18    94    126
  Queille           2007   Caucasian   France                       2       15         13    6     39    39
  Li                2008   Caucasian   USA                          40      300        465   56    350   432
  Capasso           2010   Caucasian   Italy                        30      87         123   23    122   139
  Almquist          2011   Caucasian   USA                          94      551        851   47    274   446
  Rizzato           2011   Caucasian   Hungary, Romania, Slovakia   40      186        292   46    178   297
  Leob              2012   Caucasian   USA                          4       16         35    5     19    17
  Pandish           2012   Asia        India                        19      62         25    32    78    90
  Melanomas                                                                                              
  Bastiaens         2001   Caucasian   The Netherlands              7       48         65    10    72    75
  Gwosdz            2006   Caucasian   Germany                      7       24         18    13    66    114
  Han               2006   Caucasian   USA                          15      82         104   45    297   474
  Stefanaki         2007   Caucasian   Greece                       11      44         52    6     66    73
  Li                2008   Caucasian   USA                          40      300        465   56    350   432
  Capasso           2010   Caucasian   Italy                        30      87         123   23    122   139
  SCC                                                                                                    
  Dokianakis        2000   Caucasian   Greece                       0       1          2     6     41    12
  Marshall          2000   Caucasian   England                      2       14         18    6     39    39
  Bastiaens         2001   Caucasian   The Netherlands              6       40         41    10    72    75
  Cairey-Remonnay   2002   Caucasian   France                       4       16         50    5     7     17
  McGregor          2002   Caucasian   England                      0       35         74    5     66    85
  Gustafsson        2004   Caucasian   Sweden                       5       19         30    3     31    62
  Han               2006   Caucasian   USA                          17      104        151   45    297   474
  Bendesky          2007   Other       Mexico                       3       21         18    126   94    18
  Almquist          2011   Caucasian   USA                          37      220        366   47    274   446
  Leob              2012   Caucasian   USA                          4       16         35    5     19    17
  Pandish           2012   Asia        India                        19      62         25    32    78    90
  BCC                                                                                                    
  Dokianakis        2000   Caucasian   Greece                       3       3          15    6     41    12
  Bastiaens         2001   Caucasian   The Netherlands              8       43         63    10    72    75
  McGregor          2002   Caucasian   England                      0       23         66    5     66    85
  Han               2006   Caucasian   USA                          23      108        154   45    297   474
  Pezeshki          2006   Asian       Iran                         10      47         34    86    217   162
  Bendesky          2007   Other       Mexico                       22      74         108   18    94    126
  Almquist          2011   Caucasian   USA                          57      295        485   47    274   446
  Rizzato           2011   Caucasian   Hungary, Romania, Slovakia   40      186        292   46    178   297

Most of the studies (16 of 20) were conducted in Caucasians. Of the twenty case-control studies, four only focused on melanoma \[[@B24],[@B29]-[@B31]\], five on SCC \[[@B17],[@B20],[@B22],[@B34],[@B35]\] and two on BCC \[[@B26],[@B33]\]. Four studies investigated both SCC and BCC \[[@B16],[@B21],[@B27],[@B32]\]. Two explored melanoma, SCC and BCC \[[@B18],[@B25]\]. Two studies investigated non-melanoma skin cancer, without subtype specified \[[@B19],[@B28]\]. And one explored skin cancer, histological subtype not mentioned \[[@B23]\]. The publication year was from 2000 to 2012. The sample sizes ranged from 43 to 1643. All cases were pathologically confirmed. The controls were healthy populations and matched for age, gender and ethnicity. All polymorphisms in the controls were in Hardy-Weinberg equilibrium.

Meta-analysis Results {#s3.2}
---------------------

As shown in [Table 2](#pone-0079983-t002){ref-type="table"}, no significant association between TP53 Arg72Pro polymorphism and the risk of skin cancer was observed in any genetic model and allele contrast (Pro/Pro versus Arg/Arg, odds ratio (OR) =1.07, 95% confidence interval (CI): 0.81-1.41; Pro/Arg versus Arg/Arg, OR=0.93, 95% CI: 0.77-1.13; Pro/Pro + Pro/Arg versus Arg/Arg, OR=0.93, 95% CI: 0.78-1.12; Pro/Pro versus Arg/Arg + Pro/Arg, OR=1.08, 95% CI: 0.86-1.35; Pro allele versus Arg allele, OR=0.96, 95% CI: 0.84-1.10) ([Figure 1-5](#pone-0079983-g001){ref-type="fig"}). Power calculations on the pooled frequencies indicated that the statistical powers were all lower than 80% for all the above meta-analyses.

10.1371/journal.pone.0079983.t002

###### Main results of meta-analysis for *TP53* Arg72Pro polymorphism and skin cancer risk.

  Comparative models            n    Case/Control   OR(95%CI)         P~OR~   I^2^ (%)   P~H~      Model    Power calculation
  ----------------------------- ---- -------------- ----------------- ------- ---------- --------- -------- -------------------
  Total                         20   5276/5315                                                              
  Pro allele vs. Arg allele                         0.96(0.84-1.10)   0.588   62.46      \<0.001   random   26.0%
  Pro/Pro vs. Arg/Arg                               1.07(0.81-1.41)   0.654   40.9       0.002     random   20.2%
  Pro/Arg vs. Arg/Arg                               0.93(0.77-1.13)   0.468   65.85      \<0.001   random   41.2%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       0.93(0.78-1.12)   0.459   69.52      \<0.001   random   44.5%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       1.08(0.86-1.35)   0.52    31.04      0.04      random   26.9%
  Caucasians                    16   4822/4385                                                              
  Pro allele vs. Arg allele                         0.94(0.81-1.09)   0.385   47.54      \<0.001   random   44.4%
  Pro/Pro vs. Arg/Arg                               1.05(0.77-1.43)   0.768   32.41      0.006     random   11.5%
  Pro/Arg vs. Arg/Arg                               0.88(0.72-1.06)   0.177   46.99      \<0.001   random   81.0%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       0.88(0.73-1.07)   0.203   50.61      \<0.001   random   84.4%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       1.12(0.86-1.46)   0.417   25.99      0.038     random   44.5%
  Non-Caucasians                4    454/930                                                                
  Pro allele vs. Arg allele                         1.06(0.68-1.65)   0.791   77.2       0.004     random   10.8%
  Pro/Pro vs. Arg/Arg                               1.10(0.52-2.31)   0.801   63.1       0.043     random   8.8%
  Pro/Arg vs. Arg/Arg                               1.22(0.61-2.42)   0.577   79.6       0.002     random   36.5%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       1.16(0.59-2.26)   0.671   80.5       0.001     random   24.4%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       0.95(0.66-1.36)   0.764   37.9       0.185     fixed    6.0%
  Melanoma                      6    1522/2433                                                              
  Pro allele vs. Arg allele                         1.10(0.87-1.39)   0.437   75.4       0.001     random   45.2%
  Pro/Pro vs. Arg/Arg                               1.36(0.82-2.26)   0.232   65.9       0.012     random   67.1%
  Pro/Arg vs. Arg/Arg                               0.99(0.76-1.28)   0.910   63         0.019     random   5.2%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       1.05(.079-1.39)   0.745   71.1       0.004     random   11.6%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       1.33(0.87-2.03)   0.191   54.4       0.052     fixed    62.3%
  SCC                           11   1455/2643                                                              
  Pro allele vs. Arg allele                         0.76(0.55-1.06)   0.110   85.7       \<0.001   random   100.0%
  Pro/Pro vs. Arg/Arg                               0.62(0.31-1.25)   0.182   78.2       \<0.001   random   98.2%
  Pro/Arg vs. Arg/Arg                               0.85(0.61-1.19)   0.340   73.8       \<0.001   random   80.6%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       0.75(0.51-1.12)   0.158   83.1       \<0.001   random   99.2%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       0.72(0.42-1.22)   0.219   64.1       0.002     random   83.2%
  BCC                           8    2159/3179                                                              
  Pro allele vs. Arg allele                         0.90(0.75-1.08)   0.245   66.3       0.004     random   65.5%
  Pro/Pro vs. Arg/Arg                               1.01(0.81-1.26)   0.931   30.7       0.183     fixed    5.1%
  Pro/Arg vs. Arg/Arg                               0.83(0.64-1.08)   0.163   72.5       0.001     random   88.1%
  Pro/Pro+Pro/Arg vs. Arg/Arg                       0.83(0.64-1.07)   0.140   74.1       \<0.001   random   79.1%
  Pro/Pro vs. Arg/Arg+Pro/Arg                       1.03(0.83-1.28)   0.787   22.9       0.247     fixed    5.7%

Abbreviations: OR, odds ratio; CI, confidence interval; n, number of case-control studies; P~OR~, P value of Z-test; P~H,~ P value for heterogeneity analyses; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
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In the stratified analysis by histological types of skin cancer, there was no evidence of a significant association between codon 72 polymorphism of *TP53* gene and the risk of melanoma, SCC and BCC. Similar results were found in the stratified analysis by ethnicity. Different from other subgroups, power calculations on the SCC gene models were all more than 80%, which revealed adequate sample sizes ([Table 2](#pone-0079983-t002){ref-type="table"}).

Publication Bias {#s3.3}
----------------

The publication bias was assessed by Begg's funnel plot and Egger's test. The shape of the funnel plots was seemed symmetrical and the results of Egger's test were not significant in all the genetic models (Pro/Pro versus Arg/Arg, Pro/Arg versus Arg/Arg, Pro/Pro + Pro/Arg versus Arg/Arg, Pro/Pro versus Arg/Arg + Pro/Arg, Pro allele versus Arg allele), which indicated no publication bias. [Figure 6](#pone-0079983-g006){ref-type="fig"} shows Begg\'s funnel plot of overall Pro/Pro versus Arg/Arg. In the stratified analyses by ethnicity and histological types, neither Begg's funnel plot nor Egger's test presented any obvious evidence of publication bias (data not shown). These results indicated no publication bias in our meta-analysis.

![Begg\'s funnel plot of Pro/Pro versus Arg/Arg for all studies (Begg\'s Test: P =0.284, Egger\'s test: P =0.455).](pone.0079983.g006){#pone-0079983-g006}

Discussion {#s4}
==========

*TP53* tumor suppressor gene plays an important role in the cell cycle arrest and activation of programmed cell death \[[@B8],[@B36]\]. Mutations of *TP53* gene have been detected in 50% of all human cancers and in almost all skin carcinomas \[[@B37]\]. Studies have proved that inactivation of *TP53* gene involves in the induction of skin cancer by UV radiation \[[@B11],[@B12],[@B38]\]. The most common polymorphism of *TP53* gene locates at codon 72, which is a G-C transversion, causing an amino acid change from arginine (Arg) to proline (Pro) \[[@B10]\]. The functions of the two polymorphic variants of *TP53* gene are different. According to the study conducted by Dumont et al, the Arg72 variant induces cell apoptosis markedly better than the Pro72 variant does \[[@B39]\]. Recently, many studies have explored the association between *TP53* Arg72Pro polymorphism and the susceptibility of skin cancer, but their conclusions are contradictory. Hence, we performed this meta-analysis to further investigate the influence of *TP53* Arg72Pro polymorphism on the development of skin cancer.

The results suggested that no significant association between *TP53* Arg72Pro polymorphism and the risk of skin cancer in any genetic model (Pro/Pro versus Arg/Arg, Pro/Arg versus Arg/Arg, Pro/Pro + Pro/Arg versus Arg/Arg, Pro/Pro versus Arg/Arg + Pro/Arg). In the stratified analysis by ethnicity and histological types of skin cancer, there was no evidence of a significant association, neither. Our results were similar to the meta-analysis conducted by Jiang in 2011 \[[@B40]\].

However, the results of our meta-analysis should be interpreted with caution. Except SCC subgroup, most of the power calculations on the pooled frequencies were lower than 80%, which demonstrated inadequate sample sizes.

This meta-analysis also had some limitations. First, given that only twenty studies were included, publication bias could potentially exit, even though we tried to find as many studies as we could, carefully assessed the literature and used statistical methods to minimize the publication bias, and no statistically significant publication bias was observed in this meta-analysis. Second, in the stratified analyses by ethnicity, most studies were conducted in Caucasians, and information about other ethnicities, such as African, was insufficient. Thus, more studies with larger sample size and high quality, especially for non-Caucasian populations are needed to demonstrate our conclusions in the future. Finally, the case-control study belongs to retrospective research that has methodological deficiencies.

Despite of limitations, this meta-analysis indicated that *TP53* Arg72Pro polymorphism probably had little association with the risk of skin cancer mainly in Caucasians. Nevertheless, it is still necessary to conduct larger size and better- designed studies to explore *TP53* Arg72Pro polymorphism as low statistical powers.
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